Skip to main content
Premium Trial:

Request an Annual Quote

RefSeq, Map Viewer, Ensembl 30, SZYBKI, Pathway-Express, Lithium 2.1.


The National Center for Biotechnology Information has released RefSeq 10 at The release includes genomic, transcript, and protein data available as of March 6, 2005, and includes 1,893,478 proteins and sequences from 2,827 different organisms. NCBI has also made build 1.1 of the cow genome assembly available in Map Viewer at

Ensembl 30 is now available at The release includes a new rat assembly (assembly version 3.4 from the Rat Genome Sequencing Consortium), a new cDNA database for human based on EMBL and RefSeq data, patches to variation databases, and a merge of the est and estgene databases.

OpenEye Scientific Software has released SZYBKI 1.0. Szybki (pronounced shib'kee), means "fast" in Polish. The software uses the Merck Molecular Force Field, either with or without solvent effect, to yield 3D molecular structures. According to OpenEye, SZYBKI also refines portions of a protein structure and optimizes ligands within a protein active site, making it useful in conjunction with docking programs.

The Intelligent Systems and Bioinformatics Laboratory at Wayne State University has released Pathway-Express, a new feature in the Onto-Tools software package, at The software shows where genes are located on pathways, calculates impact factors for all pathways and orders them accordingly, and allows users to browse pathways and genes. A paper describing the tool is in press for the July issue of Nucleic Acids Research.

Tripos has released Lithium 2.1. The latest version of the company's 3D molecular data desktop tool includes two components: Lithium Base, an enterprise platform that allows users to automate repetitive tasks through automatically generated procedures; and Lithium Developer, a platform that supports custom interfaces and applications.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.